Maravai Lifesciences Holdings, Inc.
A maker of the raw ingredients behind mRNA vaccines and therapies, Maravai LifeSciences supplies everything from its CleanCap® capping technology to impurity-detection kits used by biopharma and diagnostics companies in roughly sixty countries through its TriLink and Cygnus brands. Formed in 2014 by Carl Hull, Eric Tardif, and the private-equity firm GTCR, it grew by buying scientifically driven companies like TriLink and Cygnus. Its CleanCap® technology was a key ingredient in the Pfizer-BioNTech COVID-19 vaccine, and its name is the northern Italian word for "miracle."
Granted 46.3K
Granted 5.0K
Granted 46.3K
Granted 776 · Sold 50.0K
Granted 46.3K
Granted 46.3K
Granted 46.3K
Granted 46.3K
Granted 46.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Brust BerndChief Executive Officer, Director · 1 transaction | -14.2% | 2.12M | — | — | — |
| Lucier Gregory TDirector · 3 transactions | +44.8% | 622.4K | 46.3K | — | — |
| Dolan ChristineSee Remarks · 2 transactions | -5.3% | 425.3K | 5.0K | — | — |
| Eckert R AndrewDirector · 1 transaction | +12.7% | 412.2K | 46.3K | — | — |
| Oreshack KurtGeneral Counsel · 4 transactions | -21% | 335.8K | 776 | — | 50.0K |
| Gray SusannahDirector · 1 transaction | +27.2% | 216.2K | 46.3K | — | — |
| DeFord John ADirector · 1 transaction | +29.1% | 205.5K | 46.3K | — | — |
| Cunningham Sean LaurenceDirector · 1 transaction | +33.5% | 184.3K | 46.3K | — | — |
| Marker Luke JosephDirector · 1 transaction | +33.5% | 184.3K | 46.3K | — | — |
| Mihas Constantine SDirector · 1 transaction | +33.5% | 184.3K | 46.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -50.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.